Accelerated partial breast irradiation was shown to be just as effective and safe as whole breast irradiation in early-stage breast cancer patients.
Tamoxifen given to women at high risk for breast cancer lowered the rate of estrogen receptor (ER)-positive breast cancer diagnosis in the IBIS-I trial.
Fulvestrant improved overall survival compared with anastrozole, among women with treatment-naive, advanced, hormone receptor-positive breast cancer.
Data from the Women’s Intervention Nutrition Study found a reduction in dietary fat intake resulted in lower death rates in ER- and PR-negative breast cancer.
Early-stage premenopausal ER-positive breast cancer patients who have received chemotherapy benefited from ovarian suppression with tamoxifen or exemestane.
A study of triple-negative breast cancer patients found that adding bevacizumab to chemo resulted in higher pCR rates in those with basal-like disease.
The use of adjuvant capecitabine in elderly patients with moderate- to high-risk early breast cancer resulted in no improvement in disease-free survival.
Results of a phase II study of a PI3K inhibitor in ER-positive breast cancer showed a trend toward improved progression-free survival.
The PD-1 inhibitor pembrolizumab showed activity and had an acceptable safety profile in heavily pretreated metastatic triple-negative breast cancer patients.
The level of stromal tumor-infiltrating lymphocytes (Str-TILs) may influence which treatment is the most effective in women with HER2-positive breast cancer.